ArticleEuropean heart journal. Imaging methods and practice2026
Role of 3D left ventricular end-systolic volume in risk stratification and outcome prediction in significant mitral regurgitation.
Article in European heart journal. Imaging methods and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04442828 (3D Echocardiography and Cardiovascular PRognosis In Mitral REgurgitation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
3D Echocardiography and Cardiovascular PRognosis In Mitral REgurgitation (3D-PRIME)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: In the follow-up of patients with mitral regurgitation (MR), assessment of left ventricular (LV) dilatation using standard echocardiography often yields inconsistent results. We investigated whether measuring 3D LV end-systolic volume (3DLVESV) improves risk stratification in moderate or greater MR. Methods and results: In the prospective 3D Echocardiography and Cardiovascular Prognosis in Mitral Regurgitation (3D-PRIME) study, 227 patients -142 with primary (PMR) and 85 secondary MR (SMR)- underwent 2D/3D echocardiography. 3DLVESV was increased if ≥41.5/35 mL/m², and LV end-systolic diameter (LVESD) enlarged if ≥39.8/34.8 mm in men/women. The primary outcome was a composite of MR progression towards intervention, death, or heart failure hospitalization (HFH). Death or HFH was a secondary outcome.At baseline, 28% of PMR and 54% of SMR patients had increased 3DLVESV. After 21 (15-25) months, increased 3DLVESV was associated with 1.9-fold (1.2-3.2) higher adjusted risk of the primary outcome in PMR, and 4.1-fold (1.6-10.7) higher risk of death or HFH in SMR ( Conclusion: Increased 3DLVESV is associated with a higher risk of adverse events in patients with significant MR. In PMR, evaluating LV dilatation using both 3DLVESV and LVESD may enhance risk stratification and aid in patient selection for close follow-up. ClinicalTrialsgov identifier: NCT04442828, 17 April 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.